

Form PTO 1390 (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER B45110
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/509239
INTERNATIONAL APPLICATION NO. PCT/EP98/06040	INTERNATIONAL FILING DATE 17 September 1998	PRIORITY DATE CLAIMED 26 September 1997	
TITLE OF INVENTION FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS			
APPLICANT(S) FOR DO/EO/US Claudine BRUCK, Stephane Andre Georges GODART and Martine MARC-HAND			

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
☒ Please amend the specification by inserting before the first line the sentence: This is a 371 of International Application PCT/EP98/06040, filed 17 September 1998, which claims benefit from the following Provisional Application, GB 9720585.0 filed 26 September 1997.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

09509239 03260550

514 Rec'd PCT/EP 23 MAR 2000

09/509239

PATENT

ATTORNEY'S DOCKET NUMBER B45110

TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE
(DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP98/06040	17 September 1998	26 September 1997

TITLE OF INVENTION
FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS

APPLICANT(S) FOR DO/US
Claudine BRUCK, Stephane Andre Georges GODART and Martine MARC-HAND

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231
ATTENTION: DO/US

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date March 23, 2000 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL229502579US addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Susan M. Galm
(Typed or printed name of person mailing paper)

Susan M. Galm
(Signature of person mailing paper)

09/509239
416 Rec'd PCT/PTO 23 MAR 2000

Attorney Docket No. B45110

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP98/06040	17 September 1998	26 September 1997

TITLE OF INVENTION

FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS

APPLICANT(S) FOR DO/US

Claudine BRUCK, Stephane Andre Georges GODART and Martine MARC-HAND

FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Zoltan Kerekes
Attorney for Applicants
Registration No. 38,938

SMITHKLINE BEECHAM CORPORATION

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5024

Facsimile (610) 270-5090

N:\zklapps\b45110\USNATL.doc